HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy.

AbstractBACKGROUND:
More than 50% of allergic patients have house dust mite (HDM) allergy. Group 1 and 2 allergens are the major HDM allergens.
OBJECTIVE:
We sought to produce and perform preclinical characterization of a recombinant hypoallergenic combination vaccine for specific immunotherapy of HDM allergy.
METHODS:
Synthetic genes coding for 2 hybrid proteins consisting of reassembled Der p 1 and Der p 2 fragments with (recombinant Der p 2 [rDer p 2]/1C) and without (rDer p 2/1S) cysteines were expressed in Escherichia coli and purified to homogeneity by means of affinity chromatography. Protein fold was determined by using circular dichroism analysis, allergenic activity was determined by testing IgE reactivity and using basophil activation assays, and the presence of T-cell epitopes was determined based on lymphoproliferation in allergic patients. Mice and rabbits were immunized to study the molecules' ability to induce an allergic response and whether they induce allergen-specific IgG capable of inhibiting allergic patients' IgE binding to the allergens, respectively.
RESULTS:
rDer p 2/1C and rDer p 2/1S were expressed in large amounts in E coli as soluble and folded proteins. Because of the lack of disulfide bonds, rDer p 2/1S did not form aggregates and was obtained as a monomeric protein, whereas rDer p 2/1C did form aggregates. Both hypoallergens lacked relevant IgE reactivity and had reduced ability to induce allergic inflammation and allergic responses but induced similar T-cell proliferation as the wild-type allergens. Immunization with the hypoallergens (rDer p 2/1S > rDer p 2/1C) induced IgG antibodies in rabbits that inhibited the IgE reactivity of patients with HDM allergy to Der p 1 and Der p 2.
CONCLUSION:
The preclinical characterization indicates that particularly rDer p 2/1S can be used as a safe hypoallergenic molecule for both tolerance and vaccination approaches to treat HDM allergy.
AuthorsKuan-Wei Chen, Katharina Blatt, Wayne R Thomas, Ines Swoboda, Peter Valent, Rudolf Valenta, Susanne Vrtala
JournalThe Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 130 Issue 2 Pg. 435-43.e4 (Aug 2012) ISSN: 1097-6825 [Electronic] United States
PMID22789398 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Chemical References
  • Antigens, Dermatophagoides
  • Arthropod Proteins
  • Dermatophagoides pteronyssinus antigen p 2
  • Epitopes, T-Lymphocyte
  • Immunoglobulin G
  • Recombinant Fusion Proteins
  • Vaccines
  • Vaccines, Combined
  • Vaccines, Synthetic
  • Immunoglobulin E
  • Cysteine Endopeptidases
  • Dermatophagoides pteronyssinus antigen p 1
Topics
  • Animals
  • Antigens, Dermatophagoides (genetics, immunology)
  • Arthropod Proteins (genetics, immunology)
  • Cloning, Molecular
  • Cysteine Endopeptidases (genetics, immunology)
  • Epitopes, T-Lymphocyte (immunology)
  • Escherichia coli
  • Female
  • Humans
  • Hypersensitivity (immunology, prevention & control)
  • Immunoglobulin E (immunology, metabolism)
  • Immunoglobulin G (immunology, metabolism)
  • Male
  • Mice
  • Protein Binding
  • Pyroglyphidae (genetics, immunology)
  • Rabbits
  • Recombinant Fusion Proteins (genetics, immunology)
  • Vaccination
  • Vaccines (genetics, immunology, therapeutic use)
  • Vaccines, Combined
  • Vaccines, Synthetic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: